{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:10:52Z","timestamp":1789193452339,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-84809-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:07:26Z","timestamp":1735870046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Correlation analysis of the triglyceride\u2013glucose index and related parameters in metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"4","key":"84809_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol, R. et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 75(4), 865\u2013878 (2021).","journal-title":"J. Hepatol."},{"key":"84809_CR2","doi-asserted-by":"publisher","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","volume":"14","author":"RM Pipitone","year":"2023","unstructured":"Pipitone, R. M. et al. MAFLD: a multisystem disease. Ther. Adv. Endocrinol. Metab. 14, 20420188221145548 (2023).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"5","key":"84809_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CM9.0000000000002089","volume":"135","author":"SDW Bae","year":"2022","unstructured":"Bae, S. D. W., George, J. & Qiao, L. From MAFLD to hepatocellular carcinoma and everything in between. Chin. Med. J. 135(5), 547\u2013556 (2022).","journal-title":"Chin. Med. J."},{"key":"84809_CR4","first-page":"418","volume":"05","author":"CSO Hepatology","year":"2024","unstructured":"Hepatology, C. S. O. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024). Chin. J. Hepatol. 05, 418\u2013434 (2024).","journal-title":"Chin. J. Hepatol."},{"issue":"9","key":"84809_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075413","volume":"13","author":"R Yu","year":"2023","unstructured":"Yu, R. et al. Diagnostic value of triglyceride-glucose index and related parameters in metabolism-associated fatty liver disease in a Chinese population: a cross-sectional study. BMJ Open 13(9), e075413 (2023).","journal-title":"BMJ Open"},{"key":"84809_CR6","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.2147\/DMSO.S383907","volume":"15","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. Association between triglyceride-glucose index and risk of metabolic dysfunction-associated fatty liver disease: a cohort study. Diabetes Metab. Syndr. Obes. 15, 3167\u20133179 (2022).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"84809_CR7","doi-asserted-by":"crossref","unstructured":"Wang, J. et al. The diagnostic and prognostic value of the triglyceride-glucose index in metabolic dysfunction-associated fatty liver disease (MAFLD): a systematic review and meta-analysis. Nutrients 14(23), 4969 (2022).","DOI":"10.3390\/nu14234969"},{"key":"84809_CR8","doi-asserted-by":"crossref","unstructured":"Peng, H. et al. Prediction of MAFLD and NAFLD using different screening indexes: A cross-sectional study in U.S. adults. Front. Endocrinol. (Lausanne) 14, 1083032 (2023).","DOI":"10.3389\/fendo.2023.1083032"},{"issue":"1","key":"84809_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12933-022-01681-8","volume":"21","author":"SM Koh","year":"2022","unstructured":"Koh, S. M. et al. Comparison of the effects of triglyceride variability and exposure estimate on clinical prognosis in diabetic patients. Cardiovasc. Diabetol. 21(1), 245 (2022).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"84809_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070189","volume":"13","author":"M Chang","year":"2023","unstructured":"Chang, M., Shao, Z. & Shen, G. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants. BMJ Open 13(5), e070189 (2023).","journal-title":"BMJ Open"},{"issue":"1","key":"84809_CR11","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.1038\/s41598-024-60100-y","volume":"14","author":"Y Yuan","year":"2024","unstructured":"Yuan, Y. et al. Development and validation of a nomogram model for predicting the risk of MAFLD in the young population. Sci. Rep. 14(1), 9376 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"84809_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73(1), 202\u2013209 (2020).","journal-title":"J. Hepatol."},{"key":"84809_CR13","doi-asserted-by":"crossref","unstructured":"Sangro, P., De La Torre Al\u00e1ez, M. Sangro, B, et al. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. J. Physiol. Biochem. 79(4), 869\u2013879 (2023).","DOI":"10.1007\/s13105-023-00954-4"},{"issue":"7","key":"84809_CR14","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.3390\/cimb46070376","volume":"46","author":"F Khaznadar","year":"2024","unstructured":"Khaznadar, F. et al. MAFLD pandemic: updates in pharmacotherapeutic approach development. Curr. Issues Mol. Biol. 46(7), 6300\u20136314 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"84809_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12944-023-01902-3","volume":"22","author":"H Zou","year":"2023","unstructured":"Zou, H. et al. Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease. Lipids Health Dis. 22(1), 145 (2023).","journal-title":"Lipids Health Dis."},{"issue":"1","key":"84809_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-021-01561-2","volume":"20","author":"G Sheng","year":"2021","unstructured":"Sheng, G. et al. The usefulness of obesity and lipid-related indices to predict the presence of non-alcoholic fatty liver disease. Lipids Health Dis. 20(1), 134 (2021).","journal-title":"Lipids Health Dis."},{"key":"84809_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951689","volume":"13","author":"Y Xue","year":"2022","unstructured":"Xue, Y. et al. Potential screening indicators for early diagnosis of NAFLD\/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. Front. Endocrinol. (Lausanne) 13, 951689 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"84809_CR18","doi-asserted-by":"crossref","unstructured":"Taheri, E. et al. The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults. J. Diabetes Metab. Disord. 21(1) (2022).","DOI":"10.1007\/s40200-021-00941-w"},{"issue":"4","key":"84809_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1007\/s10620-024-08309-9","volume":"69","author":"ME Khamseh","year":"2024","unstructured":"Khamseh, M. E. et al. Insulin resistance\/sensitivity measures as screening indicators of metabolic-associated fatty liver disease and liver fibrosis. Dig. Dis. Sci. 69(4), 1430\u20131443 (2024).","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"84809_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12944-018-0913-3","volume":"17","author":"R Zheng","year":"2018","unstructured":"Zheng, R. et al. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease. Lipids Health Dis. 17(1), 262 (2018).","journal-title":"Lipids Health Dis."},{"key":"84809_CR21","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.2147\/DMSO.S469859","volume":"17","author":"Z Cheng","year":"2024","unstructured":"Cheng, Z. et al. The different predictive effects of multiple body fat indexes on metabolic dysfunction-associated fatty liver disease. Diabetes Metab. Syndr. Obes. 17, 3875\u20133890 (2024).","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"84809_CR22","doi-asserted-by":"crossref","unstructured":"Kim, A. H., Son, D.-H. & Lee, Y.-J. Modified triglyceride-glucose index indices are reliable markers for predicting risk of metabolic dysfunction-associated fatty liver disease: a cross-sectional study. Front. Endocrinol. (Lausanne) 14, 1308265 (2023).","DOI":"10.3389\/fendo.2023.1308265"},{"key":"84809_CR23","doi-asserted-by":"crossref","unstructured":"Alarabi, M. et al. Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation. Hepatol. Int. 18(5), 1448\u20131458 (2024).","DOI":"10.1007\/s12072-024-10701-6"},{"issue":"10","key":"84809_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam, M. et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat. Rev. Gastroenterol. Hepatol. 19(10), 638\u2013651 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"84809_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez, R. et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54(3), 1082\u20131090 (2011).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84809-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84809-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T18:03:55Z","timestamp":1735927435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-84809-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["84809"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-84809-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}